man-user-icon Client Login Portal
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    Labaton Sucharow
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Contact Us
    • Knowledge Network
    • Client Login
    • Search
    • addthis
    • link : Client Login
    • knowledge network
    Labaton Sucharow
    • Ongoing Cases
    • Settled | Resolved Cases
    • Featured Cases
      • Securities
      • Derivative
      • Mergers & Acquisitions
      • REITs and Limited Partnerships
      • Consumer Products & Data Privacy

    In re Schering-Plough Corporation / ENHANCE Securities Litigation

    Settled: October 01, 2013

    Lead plaintiffs secured a $473 million settlement in the largest securities class action settlements against a pharmaceutical company at that time.

    On October 1, 2013, the court granted final approval to a settlement with defendants Schering-Plough Corporation (Schering), Merck/Schering-Plough Pharmaceuticals (M/S-P), the individual defendants and the underwriter defendants in the amount of $473 million in cash, plus interest. The settlement resolved all claims in the action.

    Labaton Sucharow and Bernstein Litowitz Berger & Grossman LLP were the court-appointed co-lead counsel for lead plaintiffs, the Arkansas Teacher Retirement System, the Public Employees' Retirement System of Mississippi, the Louisiana Municipal Police Employees' Retirement System and the Massachusetts Pension Reserves Investment Management Board (collectively, lead plaintiffs) and the class.

    The lead plaintiffs, on behalf of the class, alleged that Schering, M/S-P, and certain of Schering's officers violated the federal securities laws, for among other reasons, failing to disclose material information concerning the commercial prospects of Vytorin (a cholesterol-lowering drug that is a combination of a drug developed by Merck (Zocor) and a drug developed by Schering (Zetia)), the commercial prospects of Zetia, and the results of a clinical trial known as ENHANCE that tested whether Vytorin was more effective than Zocor alone in reducing the intima-media thickness of the carotid arteries. The action also alleged that Schering, certain of Schering's officers, the director defendants and the underwriter defendants are statutorily responsible for false and misleading statements made in connection with offerings of Schering common stock and preferred stock in August 2007.

    If you purchased or acquired Schering common stock, six percent mandatory convertible preferred stock maturing August 13, 2012, or call options, and/or sold Schering put options, during the period between January 3, 2007 through and including March 28, 2008 (the class period), and did not sell all of those shares and/or options on or before December 11, 2007, you may be eligible to recover if you submit a Claim Form with supporting documents by November 18, 2013.

    A settlement hearing was held on October 1, 2013, at 10:00 a.m. before Judge Cavanaugh in the U.S. District Court for the District of New Jersey, in Courtroom PO 04 of the United States Post Office and Courthouse Building, Newark, NJ 07101. The deadline for objecting to the Settlement or for opting-back into the class has passed.

    Copies of relevant settlement documents can be accessed by clicking on the links to the right.

    case_study_callout_schering_2

    Case Materials

    Judgment Approving Class Action Settlement

    Preliminary Approval Order

    Stipulation and Agreement of Settlement

    Schering Settlement Notice

    Claim Form

    Motion for Final Approval of Settlement

    Motion for Attorneys' Fees and Expenses

    Joint Declaration Part 1

    Joint Declaration Part 2

    Joint Declaration Part 3

    Joint Declaration Part 4

    Joint Declaration Part 5

    Notice of Pendency

    ENHANCE Litigation Consolidated Complaint

    Useful Links

    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Center

    Our Locations

    footer-list-map_icon New York
    140 Broadway
    New York, NY 10005
    212-907-0700

    footer-list-map_icon Delaware
    222 Delaware Avenue, Suite 1510
    Wilmington, DE 19801
    302-573-2540

    Useful Links

    footer-list-map_icon Washington, D.C.
    1050 Connecticut Avenue, NW, Suite 500
    Washington, D.C. 20036
    212-907-0700

    Stay Connected

    • Facebook
    • Twitter
    • LinkedIn
    Labaton Sucharow
    • Attorney Advertising Disclaimer
    • Privacy Policy
    • Transparency in Coverage Rule
    • labaton.com
    • Labaton Sucharow All Rights Reserved 2022

    Attorney Advertising Disclaimer

    The materials appearing on this website are provided for informational purposes only and do not constitute legal advice. You should not take action based upon this information without consulting legal counsel. This site is not intended to create an attorney-client relationship. The hiring of a lawyer is an important decision that should not be based solely upon any single source of information, including advertising on this website. You may ask us to send you further information about us, and we urge you to review other sources of information about us.